INTRODUCTION
Chronic kidney disease (CKD) and hypertension are closely related in a vicious cycle; thus, blood pressure (BP) control is extremely important for patients with CKD. Both CKD and hypertension are risk factors for cardiovascular events; 1 therefore, the aim of BP control in CKD is to inhibit the progression of CKD, delay worsening of the disease to end-stage kidney disease and inhibit the occurrence of cardiovascular events.
It is well recognized that antihypertensive therapy inhibits cardiovascular events regardless of the presence or absence of CKD. 1, 2 Reducing BP is the most important intervention to delay worsening of CKD as well; it has been shown that renin-angiotensin system blockers have an added effect in patients with advanced nephropathy and albuminuria of 433.9 mg mmol À1 . 3, 4 However, the superiority of renin-angiotensin system blockers as inhibitors of CKD progression has not been demonstrated in patients with hypertension who have nephropathy and normoalbuminuria or microalbuminuria. 5, 6 A large proportion of patients with hypertension require concomitant use of two or more antihypertensive drugs to achieve the BP target of 130/80 mm Hg. 7, 8 Especially patients with CKD are often refractory to treatment and require concomitant treatment with antihypertensive drugs. 9 The results of the prespecified secondary analysis of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial showed that concomitant use of an ACE inhibitor and a Ca antagonist in patients with CKD contributed to maintain their estimated glomerular filtration rate (eGFR) more effectively than concomitant use of an ACE inhibitor and a diuretic drug. 10 However, it is not clear what types of antihypertensive drugs would effectively prevent the occurrence of cardiovascular events while maintaining the renal function of hypertensive patients with CKD when a Ca antagonist is used as the basal agent.
Benidipine is a long-acting dihydropyridine Ca antagonist; it is known that benidipine inhibits not only L-type Ca channels but also N-and T-type Ca channels and dilates renal afferent and efferent arterioles. 11, 12 It has been reported that benidipine decreases the level of urinary protein in patients with CKD more significantly than L-type Ca antagonists. 13, 14 Benidipine has also been reported to be superior to L-type Ca antagonists regarding prevention of events due to CKD progression, and may be more effective in maintaining eGFR. 15 Using the prospective, randomized, open-label, blinded endpoint (PROBE) method, the COPE trial aimed at finding the optimal drug for concomitant use with calcium-channel blocker benidipine in the treatment of hypertension. 16 It has been reported that the rate of achievement of the BP target and the prevention of cardiovascular events as the primary results were similar among benidipine-thiazide diuretic (TD), benidipine-angiotensin receptor blocker (ARB) and benidipine-b-blocker (BB) subgroups. In the secondary analysis, however, it was suggested that the benidipine-BB therapy was inferior to benidipine-TD therapy in hard end points and prevention of stroke, and inferior to benidipine-ARB therapy regarding prevention of new-onset diabetes. In the subanalysis of elderly people 65 years or older, similar findings were observed; namely, the occurrence of stroke was higher in the benidipine-BB group than in the benidipine-TD group, and that new-onset diabetes was higher than the occurrence in the benidipine-ARB group. 17 The aim of the present subanalysis of the COPE trial is to determine what types of antihypertensive drugs can prevent the occurrence of cardiovascular events and at the same time contribute to the maintenance of renal function in patients with CKD.
METHODS

Study design, setting and participants
The COPE trial was an investigator-initiated multicenter study with PROBE design that compared cardiovascular effects and achievement of target BP (o140/90 mm Hg) with three dihydropyridine calcium-channel blocker (ARB, BB or TD) benidipine-based regimens in 3501 hypertensive patients who did not achieve the target BP with benidipine alone at the dose of 4 mg per day. 16, 17 The rationale and design, trial management and the main results of the COPE trial have already been reported. 16, 17 In brief, participants with a sitting systolic BP of X140 mm Hg or a diastolic BP of X90 mm Hg, or both if untreated, or whatever the treatment, were men and women aged 40-85 years who did not achieve the target BP (o140/90 mm Hg) in the sitting position at a clinic after monotherapy with benidipine 4 mg per day during the run-in phase (4-8 weeks). These patients were randomly assigned to receive benidipine combined with an ARB, a BB or a TD. After the randomization, all patients were followed up for at least 3 years until the trial was terminated. The BP-management titration algorithm, together with other details of the study design, were as described previously. 16, 17 At each follow-up visit, we obtained information about any suspected composite end point or adverse event. The median follow-up was 3.6 years. 17 
Outcome measures
A prespecified post-hoc analysis was made to compare the cardiovascular effects of benidipine-based combination regimens (benidipine-ARB vs. benidipine-BB vs. benidipine-TD) in patients with CKD and patients without CKD. The definition of CKD is an eGFR o60 ml per minute per 1.73 m 2 or presence of urinary protein. Serum creatinine values were evaluated in all patients at the pre-randomization visit and every 6 months. Urinary protein was assessed by the qualitative dipstick method. eGFR was estimated using a modified MDRD formula adapted for the Japanese population. 18 The evaluated end points were consistent with the original trial design and included the primary and secondary end points of the COPE trial. 16 Coprimary end points: composite of cardiovascular morbidity and mortality (sudden death, fatal or non-fatal stroke, fatal or non-fatal myocardial infarction, hospitalization due to unstable angina, new onset of heart failure (New York Heart Association class II-IV), new onset or worsening of peripheral arterial disease and renal events defined as serum creatinine level doubled to over 2 mg dl À1 , serum creatinine X4.0 mg dl À1 , or renal dialysis), and achievement of target BP (o140/90 mm Hg). Secondary end points are as follows: all-cause mortality, hard composite cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke excluding transient ischemic attack), new onset of diabetes and adverse events.
Statistical methods
In total, 3293 patients who were prescribed a combination treatment (1110 patients treated with benidipine-ARB, 1089 patients treated with benidipine-BB and 1094 patients treated treated with benidipine-TD) were compared in the two groups with full set analysis to specifically evaluate benidipine-based combination therapy for the elderly in the COPE trial. 17 Patient characteristics were reported as the mean ± s.d. or percentage. Continuous variables were compared using Student's t-test or one-way analysis of variance, as appropriate. Categorical variables were compared using the w 2 -test. Blood pressure profiles were compared by analysis of variance for longitudinal data. Hazard ratios were compared using log-rank test. Confidence intervals were calculated using Cox proportional hazards model. The proportion of patients who reported adverse events was also compared using w 2 -test. eGFR profiles were compared by analysis of variance for longitudinal data. Comparisons of all time points with baseline were performed using Dunnett's test. Baseline and end of the treatment-phase urinary protein-positive rates were compared using McNemar's test. The differences among the groups were analyzed using Steel-Dwass's test. All data were analyzed using SAS System Release 9.1 (SAS Institute, Cary, NC, USA). All reported P-values are two-sided.
RESULTS
A total of 4790 patients were assessed for eligibility, and 3501 patients were randomly assigned to the benidipine-ARB (n ¼ 1167), benidipine-BB (n ¼ 1166) or benidipine-TD (n ¼ 1168) group. Each group was stratified into the following subgroups: CKD, non-CKD and unknown (Figure 1) . The group of patients stratified into unknown included the following: 471 patients with eGFR X60 ml min À1 per 1.73 m 2 and unknown urinary protein status, 1 patient with unknown eGFR status and negative urinary protein and 1 patient with unknown eGFR status and unknown urinary protein status.
Demographic and baseline characteristics of patients from the COPE trial are shown in Table 1 . Among the 3293 patients in the COPE trial, 834 patients (25.3%) had CKD, 1986 patients (60.3%) did not have CKD and 473 patients (14.3%) were in the unknown subgroup. In both the CKD and non-CKD subgroups, baseline characteristics matched well among those randomized to the three regimens.
At baseline, the mean eGFR of the CKD subgroup was 58.7±15.2 ml min À1 per 1.73 m 2 and the non-CKD subgroup was 79.1 ± 13.7 ml min À1 per 1.73 m 2 . Systolic BP in the CKD subgroup was higher at baseline (mean: 155.3 ± 11.9 mm Hg in the CKD subgroup and 153.5±11.4 mm Hg in the non-CKD subgroup), and the CKD subgroup had a higher heart rate (74.7±11.5 vs. 73.7 ± 11.0 b.p.m.). The CKD subgroup had higher rates of previous cardiovascular disease (18.5% vs. 9.5%), which were mainly stroke (4.3% vs. 1.9%) and angina pectoris (4.8% vs. 2.0%), diabetes (17.1% vs. 13.9%), reported taking more prophylactic antiplatelet agents (11.0% vs. 6.0%), statins as lipid-lowering agents (19.3% vs. 15.4%) and antidiabetic agents (9.2% vs. 6.8%), than the non-CKD subgroup.
In both the CKD and non-CKD subgroups, there was no significant difference in the change in BP among the three treatment groups (Figure 2 ). The rate of achievement of the BP target of o140/ 90 mm Hg was 63.7% in the CKD subgroup and 66.3% in the non-CKD subgroup, showing no significant difference. The rate of achievement with the benidipine-ARB, benidipine-BB and benidipine-TD therapies was 61.7%, 65.8%, and 63.6%, respectively, in the CKD subgroup and 64.6%, 66.2%, and 68.1%, respectively, in the non-CKD subgroup, showing no difference among the three therapies in the two subgroups. Table 2 shows the incidence of the primary cardiovascular composite end point and secondary end points in the benidipine-ARB, benidipine-BB and benidipine-TD groups. The incidence of the primary cardiovascular composite end point in the CKD subgroup was higher than in the non-CKD subgroup (13.8 vs. 8.1 per 1000 person-years).
Cardiovascular outcomes
As shown in Figure 3 , the hazard ratio for new-onset diabetes was significantly lower in the benidipine-ARB group than in the benidipine-TD group.
In the non-CKD subgroup, the hazard ratio for cardiovascular hard composite end points was significantly lower in the benidipine-TD group than in the benidipine-BB group. The hazard ratio for fatal and non-fatal stroke was significantly lower in the benidipine-ARB group than in the benidipine-BB group. Table 3 shows the adverse events found in the COPE trial. Overall, patients with CKD reported more adverse events than patients without CKD. Hyperuricemia, hyperkalemia and blood creatinine increases were more frequent in patients with CKD than in patients without CKD. Furthermore, in both the CKD and non-CKD subgroups, hyperuricemia was more frequently reported in the benidipine-TD groups. On the other hand, bradycardia was more frequent in the benidipine-BB groups compared with the other benidipine-based combinations in both CKD and non-CKD patients. Hypokalemia and alanine aminotranferase increases were more frequently reported in the benidipine-TD group than in the other Combination therapy for hypertension in CKD H Rakugi et al treatment groups of only the non-CKD subgroup. Hyperkalemia was more frequent only in the benidipine-ARB group of the CKD subgroup. There were no significant differences among the three regimens concerning serious adverse events in the CKD and non-CKD subgroups (Supplementary data).
Safety
Renal function
Regardless of the presence or absence of CKD, eGFR in the benidipine-ARB, benidipine-BB and benidipine-TD groups decreased from 74.0 ± 17.1, 74.2 ± 17.1 and 74.0 ± 16.7 ml min À1 per 1.73 m 2 , respectively, at baseline to 71.5 ± 17.3, 72.5 ± 17.6 and 71.2±17.0 ml min À1 per 1.73 m 2 , respectively, at the end of the treatment phase, showing no significant difference among the treatment groups. Table 4 shows the baseline characteristics of the group positive for urinary protein and the group negative for urinary protein among the patients with eGFR values X60 and o60 ml min À1 per 1.73 m 2 , respectively, and Figure 4 shows the changes in eGFR. The incidence of the primary cardiovascular composite end point was higher in the group of patients positive for urinary protein than in the group of those negative for urinary protein in both the group with eGFR levels X60 ml min À1 per 1.73 m 2 (13.4 vs. 8.1 per 1000 person-years, P ¼ 0.147) and the group with eGFR levels o60 ml min À1 per 1.73 m 2 (19.2 vs. 10.9 per 1000 person-years, P ¼ 0.234), although these differences were not significant.
As shown in Figure 4 , for the group of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 Combination
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n.s. Abbreviations: ARB, angiotensin receptor blocker; BB, b-blocker; Beni, benidipine; CKD, chronic kidney disease; TD, thiazide diuretic. Differences in the incidence of primary and secondary cardiovascular events, all-cause mortality and new-onset diabetes among the three groups and between patients with CKD and patients without CKD were compared using log-rank test.
significant difference among the treatment groups. For the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 , on the other hand, eGFR showed a small increase from 51.3 ± 7.3, 51.5 ± 6.6 and 51.9 ± 6.9 ml min À1 per 1.73 m 2 , respectively, at baseline to 54.4±14.4, 54.9±13.4 and 54.2±13.5 ml min À1 per 1.73 m 2 , respectively, at the end of the treatment phase. For the group of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 , a significant decrease in eGFR was observed in the Figure 3 Hazard ratios for primary and secondary end points: cardiovascular hard end points, fatal and non-fatal stroke and new-onset diabetes in the two groups and three treatment groups. Cardiovascular hard composite end points consisted of cardiovascular death, fatal or non-fatal myocardial infarction and stroke excluding transient ischemic attack. ARB, angiotensin receptor blocker; BB, b-blocker; Beni, benidipine; CKD, chronic kidney disease; TD, thiazide diuretic. benidipine-ARB treatment group of patients positive for urinary protein, and a significant decrease in eGFR was observed with all three therapies in patients negative for urinary protein; however, there was no significant difference among treatment groups. For the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 , no significant decrease in eGFR was observed with any treatment therapy in patients positive for urinary protein, whereas a significant increase in eGFR was observed with all three therapies in patients negative for urinary protein.
Among the 618 patients with an eGFR o60 ml min À1 per 1.73 m 2 , 327 patients (52.9%) had been evaluated for urinary protein both at baseline and at the end of the treatment phase. The number (percentage) of patients positive for urinary protein in the benidipine-ARB, benidipine-BB and benidipine-TD groups changed from 23/121 (19.0%), 11/90 (12.2%) and 19/116 (16.4%), respectively, at baseline to 20/121 (16.5%), 7/90 (7.8%) and 17/116 (14.7%), respectively, at the end of the treatment phase. No significant difference was observed among the treatment groups or between the two time points.
DISCUSSION
The results of this subanalysis of the COPE trial provide valuable data on concomitant treatment using antihypertensive drugs with a Ca antagonist as the basal agent for hypertensive patients with CKD. The results showed that in the CKD subgroup, there was no difference in the prevention of cardiovascular events among the benidipine-ARB, benidipine-BB and benidipine-TD groups. On the other hand, the results showed that the incidence of new-onset diabetes in hypertensive patients with CKD was significantly lower in the benidipine-ARB group than in the benidipine-TD group. The analysis of all patients in the COPE trial showed that the incidence of Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, b-blocker; BP, blood pressure; CCB, calcium-channel blocker; eGFR, estimated glomerular filtration rate; UP, urinary protein.
Data are shown as number of patients (%) or mean ± s.d. a P-value for UP-positive vs. UP-negative. b P-value for baseline eGFR X60 ml min À1 per 1.73 m 2 vs. Baseline eGFR o60 ml min À1 per 1.73 m 2 .
Combination therapy for hypertension in CKD H Rakugi et al new-onset diabetes was significantly lower in the benidipine-ARB group than in the benidipine-BB group. 16 Thus, the results of the COPE trial and the present ones are consistent with those reported by Elliott and Meyer 19 who found that ARB prevented the occurrence of new-onset diabetes. CKD treatment aims at preventing cardiovascular events and the progression of CKD to end-stage kidney disease; therefore, preventing a decrease of eGFR is important. Bakris et al. 20 reported that the lower the achieved BP was, the slower the decreasing speed of GFR was, and they estimated that when the BP target of 130/80 mm Hg was achieved, the speed of eGFR was approximately 1 ml min À1 per 1.73 m 2 . In the COPE trial in which a similar degree of BP control was attained, the eGFR decreased by 3 to 4 ml min À1 per 1.73 m 2 after 3 years of treatment in all treatment groups consisting of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 ; the decreasing speed was similar to that reported by Bakris et al. 20 There was no significant difference in the change in eGFR among the three treatment groups, and a similar efficacy was observed.
The group of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 was distributed into those positive and negative for urinary protein; however, even after the distribution, there was no significant difference in the change of eGFR among the three therapy groups. In the urinary protein-positive group, part of the group of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 , a significant decrease in eGFR was observed only in the benidipine plus ARB group. Bakris and Weir 21 showed in their review that eGFR decreased in the initial phase of treatment with renin-angiotensin system blockers. We assumed that in the urinary protein-positive group, although urinary protein does not reflect glomerular hyperfiltration alone, glomerular hyperfiltration resulted in a marked decrease of eGFR in the initial phase of treatment due to ARB.
In the subset analysis of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS), eGFR in the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 showed a small, but significant, increase from 49 to 55 ml min À1 per 1.73 m 2 , and the eGFR of all patients also increased from 59 to 61-62 ml min À1 per 1.73 m 2 . 22 In the COPE trial as well, eGFR increased in the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 , regardless of concomitant drugs. The eGFR decreased in all patients who participated in the COPE trial, whereas it increased in all the patients included in the JATOS study. The baseline eGFR in the COPE trial was 74 ml min À1 per 1.73 m 2 , whereas the baseline eGFR in the JATOS study was 59 ml min À1 per 1.73 m 2 because the latter study was conducted in elderly people. The reason for the finding that eGFR decreased in all patients in the COPE trial was probably because the proportion of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 was small. The reason why the eGFR was maintained or gradually increased in patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 but gradually decreased in patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 is unknown, which should be further investigated.
The fact that eGFR increased in the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 in the COPE trial is a substantial advantage in terms of progression to end-stage kidney disease. Although the mechanism of increased eGFR is not clear, it may be due to benidipine, the basal agent, because eGFR increased regardless of the addition of a concomitant drug. In the JATOS study, which also found an improvement of eGFR, efonidipine, which is Combination therapy for hypertension in CKD H Rakugi et al both an L-type and T-type Ca-channel antagonist, was used as the study drug; benidipine has also been reported to be a T-type Cachannel antagonist. 12 The effect of benidipine on T-type Ca channels may have contributed to the improvement of eGFR observed in this study. These results are consistent with a report showing that benidipine, a T/L-type Ca antagonist, inhibited renal events more effectively than L-type Ca antagonists. 15 Bardoxolon, a diabetic nephropathy drug, and pirfenidone, an antifibrinolytic drug, have also been reported to improve eGFR, and their anti-inflammatory effect and antioxidant effect are considered to be their possible mechanisms of action. 23, 24 It has been suggested that benidipine also inhibits aldosterone secretion, has an anti-inflammatory effect and an antioxidant effect based on the inhibition of T-type Ca channels in adrenal cortex glomerulosa cells, and such effects of benidipine may contribute to the improvement of eGFR. 14, 25, 26 In patients with eGFR o60 ml min À1 per 1.73 m 2 and positive for urinary protein, eGFR was maintained in all three treatment groups, and there was no significant difference in the change among the three groups. It was particularly interesting that in the urinary proteinnegative group, the eGFR significantly increased in all three groups, showing no significant difference among them in the change of eGFR. The present result is consistent with that of the AASK extension study showing that lower urinary protein levels and lower achieved BP levels are associated with improvement of eGFR. 27 In the COPE trial, the increase in eGFR in the urinary protein-negative group may have been due to glomerular hyperfiltration; therefore, the urinary proteinnegative group was divided into two groups depending on the urinary protein status at the end of the treatment phase (urinary proteinnegative group and urinary protein-positive group) to confirm the change in eGFR. In the group of patients whose urinary protein status changed from negative to positive, hyperfiltration may have occurred, but there was no increase in eGFR (49.3±6.0 vs. 49.4±12.7 ml min À1 per 1.73 m 2 at baseline and the end of treatment, respectively). In the group of patients whose urinary protein status remained negative, on the other hand, there was a remarkable increase in eGFR (52.4±5.8 vs. 58.0±12.9 ml min À1 per 1.73 m 2 , respectively); therefore, it was considered that the increase in eGFR was not due to hyperfiltration.
The ACCOMPLISH trial and the gauging albuminuria reduction with lotrel in diabetic patients with hypertension (GUARD) study, in which a renin-angiotensin system blocker was used as the basal agent, found that diuretic drugs decreased the eGFR. 28, 29 In the ACCOMPLISH trial, eGFR in the group prescribed the concomitant use of a diuretic drug decreased in all patients ( À4.22 ml min À1 per 1.73 m 2 ) and the CKD group ( À2.3 ml min À1 per 1.73 m 2 ) during the 2.9-year follow-up period. In the GUARD study, eGFR decreased by 13.64 ml min À1 during the 52-week follow-up period. In the COPE trial in which the T/L-type Ca antagonist benidipine was used as the basal agent, even in the group prescribed the concomitant use of a diuretic drug, an increase of eGFR was observed in the group of patients with a baseline eGFR o60 ml min À1 per 1.73 m 2 and without proteinuria. In CKD patients with normoalbuminuria or microalbuminuria, no correlation was found between reduction of albuminuria and the maintenance of eGFR, 30 and it was not clear whether a certain class of drugs could be effective. The results of the COPE trial suggested that strict antihypertensive treatment with a T/Ltype Ca antagonist as the basal agent was effective in CKD patients with a normal urinary protein status.
As for urinary protein, a decreasing trend was observed in all treatment groups in the COPE trial, but no significant difference was observed among treatment groups or between two time points. It has been reported that benidipine dilates efferent arterioles and inhibits proteinuria by inhibiting T-type Ca channels. [12] [13] [14] The fact that 460% of the patients included in the COPE trial already used benidipine before enrollment may have made it difficult to further inhibit proteinuria by additional treatment with a concomitant drug. The fact that urinary protein was measured in only about half of the patients by the end of the treatment phase because measurement of urinary protein was not essential in this study may have influenced the results as well.
The hazard ratio for cardiovascular hard composite end points in the non-CKD subgroup was significantly lower in the benidipine-TD group than in the benidipine-BB group, which was consistent with the results in all patients of the COPE trial. 16 On the other hand, the hazard ratio for fatal and non-fatal strokes was significantly lower in the benidipine-ARB group than in the benidipine-BB group, which differed from the finding that the hazard ratio was significantly lower in the benidipine-TD group in all patients. In the group of patients with a baseline eGFR X60 ml min À1 per 1.73 m 2 , there were 471 patients with unknown urinary protein status; these patients were excluded because it was not confirmed whether they had CKD or not. Among the excluded patients, there were four patients in the benidipine-ARB group, four patients in the benidipine-BB group and one patient in the benidipine-TD group who had developed fatal or non-fatal stroke. The number of patients excluded because of events was larger in the benidipine-ARB and benidipine-BB groups than in the benidipine-TD group, which was considered to be the reason for the difference in the results between the patients.
Study limitations
First, we adopted the PROBE design, and so non-blinded treatment allocation could have influenced the attitude of patients and investigators toward compliance with the study medications or staying in the study. Second, because the sample size of this subanalysis was relatively small, the optimal combination therapy for CKD patients should be investigated in a future trial. Third, the facts that prevention of newonset diabetes in CKD patients was inferior in the TD diuretic group and that cardiovascular hard end points and prevention of stroke in non-CKD patients were inferior in the BB group should be confirmed in future studies. Finally, measurement of urinary protein was not essential for the evaluation of renal function in this study; therefore, only about half of the patients had this parameter assessed by the end of the treatment phase. The fact that eGFR showed a small, but significant, increase in the group of patients with an eGFR o60 ml min À1 per 1.73 m 2 is important; therefore, it should be confirmed by inulin clearance, the gold standard of GFR evaluation.
In conclusion, calcium-channel blocker combined with an ARB, a BB or a TD diuretic, was similarly effective regarding prevention of cardiovascular events and the achievement of target BP in hypertensive patients with or without CKD who did not reach the target BP with 4 mg per day of benidipine alone. Concerning the effect on eGFR, there was no significant difference among the three treatment groups either; however, an improvement of eGFR was observed in the group of patients with an eGFR o60 ml min À1 per 1.73 m 2 , and there was a marked increase of eGFR especially in the urinary proteinnegative group. In CKD patients with normal proteinuria, antihypertensive treatment with a T/L-type Ca antagonist as the basal agent may be effective for maintenance of eGFR.
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